The Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences organized a webinar on “QbD Based Pharmaceutical Development” on 29th January 2026 in the Seminar Hall, New Block, NGSMIPS to enhance awareness and understanding of Quality by Design (QbD) principles among postgraduates, research scholars, and faculty members. The session was delivered by Mr. Zaheer Abbas, Sr. Formulation Scientist, Pharmaceutical Technology & Development, AstraZeneca UK Limited, Macclesfield, England.
Mr. Abbas explained the concept of Quality by Design (QbD) and its significance in modern pharmaceutical development, emphasizing it as a systematic, science- and risk-based approach that builds quality into products from the early stages rather than relying solely on end-product testing. Guidance on writing a development protocol was provided, highlighting the importance of clear objectives, scientific rationale and appropriate risk assessment. The principles of QbD and reasons for its implementation such as reducing batch failures, minimizing recalls and addressing customer complaints were discussed, along with its role in ensuring high product quality assurance, improved process understanding and regulatory flexibility. The key elements of QbD, including QTPP, CQAs, CMAs and control strategy, were explained, followed by discussions on robust process design and tools such as risk assessment methods (RPN, Ishikawa diagram, FMEA), Design of Experiments (DoE) and Process Analytical Technology (PAT). The DoE stages planning, screening, optimization and verification were outlined and PAT was highlighted as a current industry trend with examples such as online mon itoring using NIR probes integrated with processing equipment like blenders.
The session concluded with an interactive question and answer segment, where students actively participated by raising queries, followed by a formal vote of thanks.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.